HN2002000341A - Composiciones farmaceuticas para el tratamiento de la diabetis mellitus - Google Patents
Composiciones farmaceuticas para el tratamiento de la diabetis mellitusInfo
- Publication number
- HN2002000341A HN2002000341A HN2002000341A HN2002000341A HN2002000341A HN 2002000341 A HN2002000341 A HN 2002000341A HN 2002000341 A HN2002000341 A HN 2002000341A HN 2002000341 A HN2002000341 A HN 2002000341A HN 2002000341 A HN2002000341 A HN 2002000341A
- Authority
- HN
- Honduras
- Prior art keywords
- treatment
- pharmaceutical compositions
- diabetis mellitus
- diabetis
- mellitus
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE DESCRIBEN COMPOSICIONES FARMACEUTICAS SUMINISTRABLES POR VIA ORAL EN FORMA DE COMPRIMIDOS PARA EL TRTAMIENTO DE LA DIABETES MELLITIS DE TIPO II, QUE COMPRENDEN GLIBENCLAMIDA Y METFORMINA, O SUS SALES FARMACEUTICAMENTE ACEPTABLES, COMO PRINCIPIOS ACTIVOS, MANTENIDOS EN FORMA SEPARADA ENTRE ELLOS EN EL INTERIOR DE LA MISMA COMPOSICION.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001FI000230A ITFI20010230A1 (it) | 2001-11-29 | 2001-11-29 | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2002000341A true HN2002000341A (es) | 2009-12-07 |
Family
ID=11442301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2002000341A HN2002000341A (es) | 2001-11-29 | 2002-11-29 | Composiciones farmaceuticas para el tratamiento de la diabetis mellitus |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US20050053661A1 (es) |
| EP (1) | EP1458364B1 (es) |
| JP (1) | JP4474162B2 (es) |
| KR (1) | KR20040079898A (es) |
| CN (1) | CN1596103B (es) |
| AR (1) | AR037407A1 (es) |
| AT (1) | ATE387190T1 (es) |
| AU (1) | AU2002358061B2 (es) |
| BR (1) | BR0214403A (es) |
| CA (1) | CA2466677A1 (es) |
| CO (1) | CO5590906A2 (es) |
| CY (1) | CY1107966T1 (es) |
| DE (1) | DE60225331T2 (es) |
| DK (1) | DK1458364T3 (es) |
| EA (1) | EA006766B1 (es) |
| EG (1) | EG24124A (es) |
| ES (1) | ES2302862T3 (es) |
| HN (1) | HN2002000341A (es) |
| HR (1) | HRP20040501A2 (es) |
| HU (1) | HUP0402154A3 (es) |
| IL (1) | IL162143A0 (es) |
| IT (1) | ITFI20010230A1 (es) |
| MA (1) | MA27087A1 (es) |
| MX (1) | MXPA04004974A (es) |
| MY (1) | MY141243A (es) |
| NO (1) | NO20042713L (es) |
| NZ (1) | NZ533779A (es) |
| PA (1) | PA8559801A1 (es) |
| PE (1) | PE20030580A1 (es) |
| PL (1) | PL206016B1 (es) |
| PT (1) | PT1458364E (es) |
| RS (1) | RS50937B (es) |
| SI (1) | SI1458364T1 (es) |
| SV (1) | SV2004001415A (es) |
| TN (1) | TNSN04095A1 (es) |
| UA (1) | UA81615C2 (es) |
| UY (1) | UY27549A1 (es) |
| WO (1) | WO2003045355A1 (es) |
| ZA (1) | ZA200404880B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2434169C (en) * | 2001-01-12 | 2011-03-15 | Sun Pharmaceutical Industries Limited | Spaced drug delivery system |
| US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| HUE034290T2 (en) | 2003-04-29 | 2018-02-28 | Orexigen Therapeutics Inc | Preparations containing opioid antagonist and bupropion to affect weight loss |
| UY29445A1 (es) * | 2005-03-30 | 2006-10-02 | Generex Pharm Inc | Composiciones para la transmisión transmucosa oral de la metformina |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI609702B (zh) * | 2006-11-09 | 2018-01-01 | 歐瑞根治療有限公司 | 層狀醫藥調配物 |
| ITMI20062254A1 (it) * | 2006-11-24 | 2008-05-25 | Acraf | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
| JP2011521973A (ja) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
| CA2638240C (en) | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
| RU2398572C1 (ru) * | 2009-05-18 | 2010-09-10 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ лечения больных сахарным диабетом 2 типа |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| RU2483717C2 (ru) * | 2010-11-22 | 2013-06-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция для лечения диабета (варианты) |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| EP2661266B1 (en) | 2011-01-07 | 2020-09-16 | Anji Pharma (US) LLC | Chemosensory receptor ligand-based therapies |
| US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| KR20190120430A (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| EP2800562A2 (en) | 2012-01-06 | 2014-11-12 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| LT3730132T (lt) | 2012-06-06 | 2022-08-25 | Nalpropion Pharmaceuticals Llc | Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde |
| JP6075818B2 (ja) | 2014-11-11 | 2017-02-08 | 塩野義製薬株式会社 | 光に対して不安定な薬物を含有する多層錠剤 |
| KR101750690B1 (ko) * | 2015-10-28 | 2017-06-27 | 주식회사 종근당 | 메트포르민 및 로베글리타존을 포함하는 약제학적 조성물 |
| CN105596339A (zh) * | 2015-12-23 | 2016-05-25 | 青岛海之源智能技术有限公司 | 一种二甲双胍阿昔莫司复方组合物及制备方法 |
| AU2019278015B2 (en) | 2018-05-31 | 2024-10-03 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof |
| CN110128305A (zh) * | 2019-05-10 | 2019-08-16 | 天津大学 | 二甲双胍-甲苯磺丁脲新盐型、其制备方法及医药用途 |
| JP2021120357A (ja) * | 2020-01-30 | 2021-08-19 | サンノーバ株式会社 | 錠剤 |
| GB2599950A (en) * | 2020-10-16 | 2022-04-20 | Zentiva Ks | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same |
| CN113143940A (zh) * | 2020-12-30 | 2021-07-23 | 成都恒瑞制药有限公司 | 一种抗糖尿病药物组合物的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2347531A1 (de) * | 1973-09-21 | 1975-04-30 | Hoechst Ag | Arzneizubereitungen zur oralen diabetes-behandlung |
| IT1276130B1 (it) * | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
| AP1224A (en) * | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
| ES2206868T3 (es) * | 1998-07-15 | 2004-05-16 | Merck Sante | Comprimidos que comprenden una combinacion de metformin glibenclamida. |
| US6780432B1 (en) * | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
| CA2434169C (en) * | 2001-01-12 | 2011-03-15 | Sun Pharmaceutical Industries Limited | Spaced drug delivery system |
-
2001
- 2001-11-29 IT IT2001FI000230A patent/ITFI20010230A1/it unknown
-
2002
- 2002-11-22 AR ARP020104498A patent/AR037407A1/es unknown
- 2002-11-25 MY MYPI20024393A patent/MY141243A/en unknown
- 2002-11-26 PE PE2002001140A patent/PE20030580A1/es not_active Application Discontinuation
- 2002-11-26 UY UY27549A patent/UY27549A1/es not_active Application Discontinuation
- 2002-11-27 EG EG2002111281A patent/EG24124A/xx active
- 2002-11-28 SV SV2002001415A patent/SV2004001415A/es not_active Application Discontinuation
- 2002-11-29 KR KR10-2004-7006874A patent/KR20040079898A/ko not_active Ceased
- 2002-11-29 ES ES02791739T patent/ES2302862T3/es not_active Expired - Lifetime
- 2002-11-29 JP JP2003546858A patent/JP4474162B2/ja not_active Expired - Lifetime
- 2002-11-29 US US10/497,022 patent/US20050053661A1/en not_active Abandoned
- 2002-11-29 UA UA20040504085A patent/UA81615C2/ru unknown
- 2002-11-29 PA PA20028559801A patent/PA8559801A1/es unknown
- 2002-11-29 IL IL16214302A patent/IL162143A0/xx not_active IP Right Cessation
- 2002-11-29 CN CN028236920A patent/CN1596103B/zh not_active Expired - Fee Related
- 2002-11-29 DE DE60225331T patent/DE60225331T2/de not_active Expired - Lifetime
- 2002-11-29 MX MXPA04004974A patent/MXPA04004974A/es active IP Right Grant
- 2002-11-29 PT PT02791739T patent/PT1458364E/pt unknown
- 2002-11-29 HU HU0402154A patent/HUP0402154A3/hu unknown
- 2002-11-29 HN HN2002000341A patent/HN2002000341A/es unknown
- 2002-11-29 EP EP02791739A patent/EP1458364B1/en not_active Expired - Lifetime
- 2002-11-29 AT AT02791739T patent/ATE387190T1/de not_active IP Right Cessation
- 2002-11-29 AU AU2002358061A patent/AU2002358061B2/en not_active Ceased
- 2002-11-29 NZ NZ533779A patent/NZ533779A/en not_active IP Right Cessation
- 2002-11-29 CA CA002466677A patent/CA2466677A1/en not_active Abandoned
- 2002-11-29 PL PL369851A patent/PL206016B1/pl not_active IP Right Cessation
- 2002-11-29 HR HRP20040501 patent/HRP20040501A2/hr not_active Application Discontinuation
- 2002-11-29 SI SI200230693T patent/SI1458364T1/sl unknown
- 2002-11-29 BR BR0214403-4A patent/BR0214403A/pt not_active IP Right Cessation
- 2002-11-29 EA EA200400664A patent/EA006766B1/ru not_active IP Right Cessation
- 2002-11-29 WO PCT/EP2002/013497 patent/WO2003045355A1/en not_active Ceased
- 2002-11-29 DK DK02791739T patent/DK1458364T3/da active
-
2004
- 2004-05-24 MA MA27696A patent/MA27087A1/fr unknown
- 2004-05-28 TN TNP2004000095A patent/TNSN04095A1/en unknown
- 2004-05-28 RS YUP-473/04A patent/RS50937B/sr unknown
- 2004-06-21 ZA ZA200404880A patent/ZA200404880B/en unknown
- 2004-06-28 NO NO20042713A patent/NO20042713L/no not_active Application Discontinuation
- 2004-06-29 CO CO04061363A patent/CO5590906A2/es not_active Application Discontinuation
-
2008
- 2008-05-26 CY CY20081100543T patent/CY1107966T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2002000341A (es) | Composiciones farmaceuticas para el tratamiento de la diabetis mellitus | |
| IL184051A (en) | Acetylated GLP-1 compounds, containing and using pharmaceutical preparations | |
| CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
| UY28510A1 (es) | Compuestos quimicos | |
| AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
| ECSP055853A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos | |
| UY27891A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para la preparación de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos. | |
| CL2009001170A1 (es) | Composicion farmaceutica para administracion oral que comprende 5-azacitidina de liberacion inmediata sin recubrimiento enterico; y su uso para el tratamiento de una enfermedad asociada a la proliferacion anormal de celulas, tal como sindrome mielodisplasico, leucemia mielogena aguda y cancer de pulmon, entre otros. | |
| CL2009001059A1 (es) | Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras. | |
| GT200600517A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| CL2008002227A1 (es) | Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad. | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
| CR9667A (es) | Derivados de benzamida y usos relacionados con los mismos | |
| ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
| UY28990A1 (es) | Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso. | |
| DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| ECSP088250A (es) | Derivados de pirazol como agentes terapéuticos | |
| PE20110677A1 (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275) | |
| GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
| UY29244A1 (es) | Combinaciones medicas | |
| GT200600157A (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
| UY29790A1 (es) | Sales de diariloimidazola-4-carboxamidas, composiciones que las contienen, procesos de preparación y aplicaciones | |
| AR058361A1 (es) | Composiciones lifolizadas de un compuesto de triazolopirimidina | |
| NO20064808L (no) | Orale matrixformuleringer med licarbazepin |